Bill & Melinda Gates Medical Research Institute

Last updated
The Bill & Melinda Gates Medical Research Institute
EstablishedJanuary 2018;5 years ago (2018-01)
Founders
Bill Gates
Founded at Cambridge, Massachusetts
Type Nonprofit
PurposeMedical research
Location
Region served
Global
Key people
  • Emilio A. Emini (CEO)
  • Michael Dunne (CMO)
Parent organization
 Bill & Melinda Gates Foundation
Budget (2018)
US$100 million
FundingBill & Melinda Gates Foundation
Endowment (2018)$273 million
Website www.gatesmri.org

The Bill & Melinda Gates Medical Research Institute (Gates MRI) is a non-profit biotechnology organization founded with the aim of bringing technologies and strategies to bear on the main health problems of the poor in low-income countries. [1] The Gates MRI was organized as a subsidiary of the Bill & Melinda Gates Foundation who funded it with a $273 million 4-year grant. [2] [3]

Contents

Activities

Upon its founding, the organization said it would focus on the early stages of research for cures and treatments before working with larger companies for large-scale production once proof of effectiveness had been established. [4] The Gates MRI has been described as a "nonprofit biotechnology company". [5] According to Forbes , the organization focuses on developing treatments for diseases such as malaria, tuberculosis, and diseases which cause diarrhea. [5] Combined, these three diseases alone cause five deaths every minute. [6] [2] Chief executive officer Emilio A. Emini said the organization focuses in particular on diseases that are most present in low and middle income countries, where investment in treatments by large pharmaceutical companies is "limited and insufficient." [7]

History

Gates MRI was founded in January 2018 in Cambridge, Massachusetts, as a nonprofit offshoot of the Bill & Melinda Gates Foundation. [8] [5]

Projects

Among its first steps toward product development, Gates MRI announced plans to try and replicate earlier clinical findings that showed revaccinating adolescents against tuberculosis with the Bacillus Calmette–Guérin (BCG) vaccine could give them added protection. [5] This vaccine is typically given to children when they are infants, but Phase 2 data suggests that also vaccinating at-risk adolescents may confer added preventative effect. [9] No commercial firm has yet been interested in testing this approach to extending tuberculosis immunization. As of May 2022, that research was still in clinical trials, expected to conclude in 2026. [10]

In 2019, Gates MRI expanded the scope of its mission to include maternal, newborn, and child health (MN2CH), in part driven by the health needs in these groups. In 2019 alone, worldwide 2.4 million children died during their first month of life, [11] while more than 800 women die every day from preventable causes related to pregnancy and childbirth. [12]

Since then, the group has partnered with several others to explore treatments for various diseases. In 2020, Gates MRI partnered with Evotec, Johnson & Johnson, Otsuka Pharmaceutical, GSK plc, and TB Alliance to create the Project to Accelerate New Treatments for Tuberculosis (PAN-TB), a group working on developing new treatment regimens for tuberculosis. [13] Gates MRI licensed the M72 TB vaccine from GSK in 2020 and began an observational epidemiology study on latent TB infection in preparation for Phase III trials. [14] [10]

In 2021, the Gates MRI partnered with the biotechnology firm Atreca to license a monoclonal antibody treatment for malaria. [15] In August 2022, plans for Phase II trials for a new tuberculosis treatment developed by PAN-TB were announced. [13] Gates MRI partnered with Merck Group in 2022 to further develop drugs to treat drug-resistant strains of TB. [16]

Leadership

The organization was led from its founding until 2021 by Penny Heaton. [17] [18] She was succeeded by Emilio A. Emini. Gates MRI is led by Emini and chief medical officer Michael Dunne. [19] [20]

Related Research Articles

<span class="mw-page-title-main">Bill & Melinda Gates Foundation</span> Private foundation founded by Bill and Melinda Gates

The Bill & Melinda Gates Foundation (BMGF), a merging of the William H. Gates Foundation and the Gates Learning Foundation, is an American private foundation founded by Bill Gates and Melinda French Gates. Based in Seattle, Washington, it was launched in 2000 and is reported as of 2020 to be the second largest charitable foundation in the world, holding $49.8 billion in assets. On his 43rd birthday, Bill Gates gave the foundation $1 billion. The primary stated goals of the foundation are to enhance healthcare and reduce extreme poverty across the world, and to expand educational opportunities and access to information technology in the U.S. Key individuals of the foundation include Bill Gates, Melinda French Gates, Warren Buffett, chief executive officer Mark Suzman, and Michael Larson.

<span class="mw-page-title-main">GSK plc</span> British multinational pharmaceutical and biotechnology company

Since October 2018, the Center for Global Infectious Disease Research has been part of the Seattle Children's Research Institute. At the time of the merger, CID Research had 166 scientists. Its mission was to eliminate the world's most devastating infectious diseases through leadership in scientific discovery. The organization's research labs were in the South Lake Union area of Seattle, WA. The institute's research focused on four areas of infectious disease: HIV/AIDS, malaria, tuberculosis (TB), and Emerging & Neglected Diseases (END) like African sleeping sickness, leishmaniasis, Chagas disease, and toxoplasmosis. CID Research was engaged in early stages of the scientific pipeline including bench science and malaria clinical trials and has expertise in immunology, vaccinology, and drug discovery.

The European and Developing Countries Clinical Trials Partnership (EDCTP) is a partnership between the European Union (EU), Norway, Switzerland and developing countries and other donors, as well as the pharmaceutical industry, to enable clinical trials and the development of new medicines and vaccines against HIV/AIDS, tuberculosis, and malaria. The need for global action against these diseases in order to promote poverty reduction has been recognised by the United Nations, the G8, and the African Union, and the program envisioned the provision of €600 million for the period 2003–2007 in order to translate medical research results into clinical applications relevant to the needs of developing countries.

<span class="mw-page-title-main">PATH (global health organization)</span> Global health nonprofit

PATH is an international, nonprofit global health organization. PATH is based in Seattle with 1,600 employees in more than 70 countries around the world. Its president and CEO is Nikolaj Gilbert, who is also the Managing Director and CEO of Foundations for Appropriate Technologies in Health (FATH), PATH's Swiss subsidiary. PATH focuses on six platforms: vaccines, drugs, diagnostics, devices, system, and service innovations.

Malaria vaccines are vaccines that prevent malaria, a mosquito-borne infectious disease which annually affects an estimated 247 million people worldwide and causes 619,000 deaths. The first approved vaccine for malaria is RTS,S, known by the brand name Mosquirix. As of April 2023, the vaccine has been given to 1.5 million children living in areas with moderate-to-high malaria transmission. It requires at least three doses in infants by age 2, and a fourth dose extends the protection for another 1–2 years. The vaccine reduces hospital admissions from severe malaria by around 30%.

<span class="mw-page-title-main">African Malaria Network Trust</span> Non-governmental organization

The African Malaria Network Trust (AMANET) is a pan-African international NGO headquartered in Dar es Salaam, Tanzania. It originally started its activities as African Malaria Vaccine Testing Network (AMVTN) in 1995 with the primary goal of preparing Africa in planning and conducting malaria vaccine trials. In order to widen the scope in malaria interventions, AMVTN was succeeded by AMANET on 14 March 2002. Although the primary goal of AMANET has remained malaria vaccine development, the organization in its expanded role includes other intervention measures such as antimalaria drugs and vector control.

<span class="mw-page-title-main">FIND, the global alliance for diagnostics</span> Swiss global health nonprofit organization

FIND is a global health non-profit based in Geneva, Switzerland. FIND functions as a product development partnership, engaging in active collaboration with over 150 partners to facilitate the development, evaluation, and implementation of diagnostic tests for poverty-related diseases. The organisation's Geneva headquarters are in Campus Biotech. Country offices are located in New Delhi, India; Cape Town, South Africa; and Hanoi, Viet Nam.

The International Vaccine Institute (IVI) is an independent, nonprofit, international organization founded on the belief that the health of children in developing countries can be dramatically improved by the use of new and improved vaccines. Working in collaboration with the international scientific community, public health organizations, governments, and industry, IVI is involved in all areas of the vaccine spectrum – from new vaccine design in the laboratory to vaccine development and evaluation in the field to facilitating sustainable introduction of vaccines in countries where they are most needed.

<span class="mw-page-title-main">Stefan H. E. Kaufmann</span>

Stefan Hugo Ernst Kaufmann is a German immunologist and microbiologist and is one of the highly cited immunologists worldwide for the decade 1990 to 2000. He is amongst the 0.01% most cited scientists of ca. 7 million scientists in 22 major scientific fields globally.

<span class="mw-page-title-main">Infectious Disease Research Institute</span>

The Infectious Disease Research Institute (IDRI) is a non-profit organization based in Seattle, in the United States, and which conducts global health research on infectious diseases.

<span class="mw-page-title-main">RTS,S</span> Malaria vaccine

RTS,S/AS01 is a recombinant protein-based malaria vaccine. It is the only malaria vaccine approved and in wide use. As of April 2022, the vaccine has been given to 1 million children living in areas with moderate-to-high malaria transmission, with millions more doses to be provided as the vaccine's production expands. It requires at least three doses in infants by age 2, with a fourth dose extending the protection for another 1-2 years. The vaccine reduces hospital admissions from severe malaria by around 30%.

Sir Stewart Thomas Cole is a British/French microbiologist. He has been the director general of the Pasteur Institute since January 2018.

The Global Health Innovative Technology Fund, headquartered in Japan, is an international public-private partnership between the Government of Japan, 16 pharmaceutical and diagnostics companies, the Bill & Melinda Gates Foundation, the Wellcome Trust and United Nations Development Programme. It funds scientific research and development for anti-infectives and diagnostics for diseases that primarily affect the developing world. Bill Gates has noted that "GHIT draws on the immense innovation capacity of Japan’s pharmaceutical companies, universities and research institutions to accelerate the creation of new vaccines, drugs and diagnostic tools for global health." Margaret Chan, former Director-General of the World Health Organization, said: "The GHIT Fund has stepped in to provide that incentive in a pioneering model of partnership that brings Japanese innovation, investment and leadership to the global fight against infectious disease."

Barry R. Bloom is Harvard University Distinguished Service Professor and Joan L. and Julius H. Jacobson Professor of Public Health in the Department of Immunology and Infectious Diseases and Department of Global Health and Population in the Harvard T.H. Chan School of Public Health in Boston, where he served as dean of the faculty from 1998 through December 31, 2008.

This page is a timeline of global health, including major conferences, interventions, cures, and crises.

Gagandeep Kang FRS is an Indian Microbiologist and virologist who is the Professor in the Department of Gastrointestinal Sciences at the Christian Medical College, Vellore, India and from August 2016 to July 2020 was executive director of the Translational Health Science and Technology Institute, Faridabad, an autonomous institute of the Department of Biotechnology, Ministry of Science and Technology, Government of India. She is a leading researcher with a major research focus on viral infections in children, and the testing of rotaviral vaccines. She also works on other enteric infections and their consequences when children are infected in early life, sanitation and water safety. She was awarded the prestigious Infosys Prize in Life Sciences in 2016 for her contributions to understanding the natural history of rotavirus and other infectious diseases. In 2019, she became the first Indian woman to be elected as a Fellow of the Royal Society. She was on the Life Sciences jury for the Infosys Prize in 2020.

Francine NtoumiPh.D., HDR, PvDz, FRCPedin is a Congolese parasitologist specializing in malaria. She was the first African person in charge of the secretariat of the Multilateral Initiative on Malaria (2006-2010). In recent years, she has become involved in research on other infectious diseases, including COVID-19.

Penny M. Heaton is an American physician who is the Global Therapeutics Lead for Vaccines at Johnson & Johnson. She previously worked at Novavax, Novartis and the Bill & Melinda Gates Foundation. She was included by Stat News on their definitive list of leaders in the life sciences in 2022.

MedAccess is a social finance company based in London. It is capitalized at $200 million, enabling it to provide loans and financial guarantees designed to increase access to health products, including vaccines, therapeutics, and diagnostic tests, for patients in low- and middle-income countries.

References

  1. ↑ "Bill & Melinda Gates Medical Research Institute". www.gatesmri.org.
  2. 1 2 Branswell, H (2018). The Gates Foundation rolls out details of its new biotech, one without a profit motive. STAT.
  3. ↑ Chepkemoi, J. (25 April 2017). "The Wealthiest Charitable Foundations In the World". WorldAtlas. Retrieved 12 December 2022.
  4. ↑ Taylor, Nick Paul (June 8, 2018). "Gates Foundation's $100M-a-year nonprofit biotech takes flight". Fierce Biotech. Retrieved August 24, 2022.
  5. 1 2 3 4 Herper, Matthew (June 7, 2018). "Bill And Melinda Gates Start A Nonprofit Biotech In Boston". Forbes . Retrieved August 24, 2022.
  6. ↑ WHO Diarrheal disease fact sheet, updated May 2017; , WHO Global Tuberculosis Report 2017; WHO Malaria Policy and Advisory Committee Meeting Report 2018.[WHO Malaria Policy and Advisory Committee Meeting Report 2018]
  7. ↑ "Member Spotlight: Q&A with The Bill & Melinda Gates Medical Research Institute". MassBio. August 1, 2022. Retrieved September 28, 2022.
  8. ↑ Branswell, Helen (June 7, 2018). "The Gates Foundation rolls out details of its new biotech, one without a profit motive". Stat . Retrieved August 24, 2022.
  9. ↑ Nemes, et al. NEJM (July 12, 2018) "Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.
  10. 1 2 Stent, James (May 10, 2022). "This vaccine could save tens of thousands of South African lives each year, but we'll only see it in 2030". News24 . GroundUp . Retrieved August 24, 2022.
  11. ↑ "Newborns: improving survival and well-being". www.who.int. World Health Organization. Retrieved 6 January 2023.
  12. ↑ (Feb. 2018). Maternal mortality. World Health Organization
  13. 1 2 Mireku, Akosua (August 26, 2022). "PAN-TB's Phase II trials take a shot at shorter TB regimens". Pharmaceutical Technology. Retrieved September 28, 2022.
  14. ↑ Arthur, Rachel (April 5, 2022). "Gates MRI looks to Phase 3 tuberculosis vaccine trial with epidemiology study". Biopharma Reporter. Retrieved October 25, 2022.
  15. ↑ LaHucik, Kyle (October 21, 2021). "GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody". Fierce Biotech. Retrieved August 24, 2022.
  16. ↑ Masson, Gabrielle (October 18, 2022). "Bill & Melinda Gates Institute licenses 2 of Merck's TB antibiotic candidates". Fierce Biotech. Retrieved October 25, 2022.
  17. ↑ McGrane, Clare (June 11, 2018). "Gates Foundation's new research institute officially opens, targeting malaria and other global diseases". GeekWire . Retrieved August 24, 2022.
  18. ↑ Branswell, Helen (November 17, 2021). "Johnson and Johnson's new vaccines leader talks Covid-19, pipeline plans, and 'a golden opportunity' for clinical trials". Stat. Retrieved August 24, 2022.
  19. ↑ "Emilio A. Emini". The Bill & Melinda Gates Medical Research Institute. Retrieved September 20, 2022.
  20. ↑ "Gates Medical Research Institute – Tuberculosis Research". Health Professional Radio. September 1, 2022. Retrieved September 28, 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.